The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis

What Was Tested

This randomized controlled trial paper looks at Glatiramer Acetate in the context of multiple sclerosis.

Two definitions of T1 hypointense (T1H) lesions can be derived from pre-contrast images: those that may or may not have a corresponding gadolinium-enhancing correlate on post-contrast images (T1H total), and those that are simultaneously non-gadolinium-enhancing on post-contrast scans (T1H non-enhancing).

Who Took Part

According to the abstract, 1404 subjects were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The Phase III GALA study randomized 1404 RRMS subjects 2:1 to receive GA40 or placebo for 12 months.

A total of 1,357 patients had MRI data collected at either the month 6 or month 12 visit.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Glatiramer Acetate and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Glatiramer Acetate could be set against what happens without it.

The timeline in the abstract includes 12 months.

MRI scans were obtained at baseline and at months 6 and 12.

Cumulative numbers of T1H total and of T1H non-enhancing lesions were analyzed using an adjusted negative binomial regression model.

What Was Measured

PubMed files the paper under topics including Brain, Gadolinium, Glatiramer Acetate, Immunosuppressive Agents, Magnetic Resonance Imaging and Multiple Sclerosis, Relapsing-Remitting.

The authors tagged it with the keywords T1 hypointense lesions, gadolinium-enhancing lesions and relapsing-remitting multiple sclerosis.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Glatiramer Acetate in 1404 subjects in people with multiple sclerosis over 12 months.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Journal of neuroimaging : official journal of the American Society of Neuroimaging), a journal based in United States.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.